Critical Illness
Recent clinical, regulatory, research and industry developments relating to this disease.
Pathogenesis and therapeutic opportunities of gut microbiome dysbiosis in critical illness.
Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients-A Narrative Review.
The metabolic effects of intermittent versus continuous feeding in critically ill patients.
Whole-genome sequencing reveals host factors underlying critical COVID-19.
Mapping the human genetic architecture of COVID-19.
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.
Genetic mechanisms of critical illness in COVID-19.
Risk factors for severe and critically ill COVID-19 patients: A review.
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027Effect of Protocolized Magnesium Replacement in Critically Ill Patients on Mortality and Atrial Fibrillation: the MAGNOLIA Randomized Controlled Trial
- Q1 2027The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)
- Q1 2028Parenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility Study
Clinical MilestonesViewHide
- 2025-10-02Efficacy of Self-management of Sedative Therapy by Ventilated ICU PatientsResults posted
- 2026-04-27Effect of Protocolized Magnesium Replacement in Critically Ill Patients on Mortality and Atrial Fibrillation: the MAGNOLIA Randomized Controlled TrialResults expected Q1 2027
- 2025-11-21The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)Results expected Q1 2027
- 2025-09-22Parenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility StudyResults expected Q1 2028
- 2026-07-05ClinicalThe Effect of Lactoferrin in Improving Clinical Outcomes in ICU PatientsCompleted
- 2026-04-27ClinicalEffect of Protocolized Magnesium Replacement in Critically Ill Patients on Mortality and Atrial Fibrillation: the MAGNOLIA Randomized Controlled TrialResults expected Q1 2027
- 2026-03-01ClinicalPreventing Cardiovascular Collapse With Vasopressors During Tracheal Intubation. The PREVENTION Randomized Multicenter StudyPrimary completion
- 2025-11-21ClinicalThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)Results expected Q1 2027
- 2025-10-02ClinicalEfficacy of Self-management of Sedative Therapy by Ventilated ICU PatientsResults posted
- 2025-09-22ClinicalParenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility StudyResults expected Q1 2028
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Critical Illness6
- COVID-193
- Gastrointestinal Microbiome2
- Host-Pathogen Interactions2
- Acute Kidney Injury1
- Amino Acids1
- Attitude of Health Personnel1
- Betacoronavirus1
Leading journals6
- Nature3
- Science (New York, N.Y.)2
- Allergy1
- Blood advances1
- BMC gastroenterology1
- Diabetes/metabolism research and reviews1
Leading researchers8
- Abel L2
- Aiuti A2
- Baillie JK2
- Bastard P2
- Beaussant Y2
- Belot A2
- Béziat V2
- Bilguvar K2
Affiliations (unnormalised)6
- Karolinska Institutet3
- School of Life Sciences3
- William Harvey Research Institute3
- Aarhus University2
- Aarhus University Hospital2
- Avicenne Hospital2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Critical illness is a disease or state in which death is possible or imminent. The supplied literature frames it as a severe clinical state associated with high mortality and the need for intensive management, often discussed in the context of severe infections and organ dysfunction.
The grounding does not support a single cause for critical illness as a general state. It is discussed in association with severe infections, sepsis, trauma-related illness, hypovolaemic shock, and severe COVID-19, but these are examples of conditions linked to critical deterioration rather than a complete aetiology.
The supplied material does not define a single unified mechanism for critical illness. It points to diverse pathophysiological processes depending on the underlying condition, including impaired intestinal barrier function and permeability, host-pathogen interactions, immune dysregulation, acute kidney injury, coagulation disorders, thromboembolism, and abnormal type I interferon responses in severe viral disease.
Risk factors are supported mainly in the context of progression to severe or critical COVID-19. These include old age, male sex, obesity, diabetes, hypertension, chronic lung disease, heart, liver and kidney disease, tumors, clinically apparent immunodeficiencies, local immunodeficiencies such as reduced early type I interferon secretion capacity, and pregnancy.
The grounding supports intensive supportive and disease-directed therapy at the level of broad modality rather than specific regimens. It also indicates management of associated complications such as acute kidney injury, coagulation disorders, and thromboembolism, with treatment approaches varying by the underlying cause and severity of illness.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A disease or state in which death is possible or imminent.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.